MedTrace Logo

Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry)

NCT04790032 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-08-07

No results posted yet for this study

Summary

This prospective registry was designed to carefully investigate the pharmacodynamic (PD) effects of cangrelor in all patients undergoing percutaneous coronary intervention (PCI).

Conditions

  • Percutaneous Coronary Intervention

Interventions

DRUG

Cangrelor

All patients receiving Cangrelor during PCI will be enrolled and analyzed for platelet function tests.

Sponsors & Collaborators

  • Federico II University

    lead OTHER

Principal Investigators

  • Giuseppe Gargiulo, MD, PhD · Department of Advanced Biomedical Sciences, University Federico II of Naples, Italy

  • Giovanni Esposito, MD, PhD · Department of Advanced Biomedical Sciences, University Federico II of Naples, Italy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-16
Primary Completion
2024-07-01
Completion
2024-07-01
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04790032 on ClinicalTrials.gov